Aktuelle smitsomme sygdomme
Søgeord (paxlovid) valgt.
8 emner vises.
Medscape Infectious Diseases, 29.07.2024
Tilføjet 29.07.2024
With no standard approved long COVID therapies, research turns to a proven COVID drug and other \'low-risk, high-reward\' help. Medscape Medical News
Læs mereMedscape Infectious Diseases, 5.04.2024
Tilføjet 5.04.2024
Clinicians should still consider prescribing the drug to adults over age 65 or those who are immunocompromised, experts said. Medscape Medical News
Læs mereMedscape Infectious Diseases, 15.02.2024
Tilføjet 15.02.2024
The EMA has warned that Paxlovid should only be administered alongside tacrolimus, ciclosporin, everolimus, or sirolimus if their blood levels can be closely monitored. Medscape Medical News
Læs mereMedscape Infectious Diseases, 31.10.2023
Tilføjet 31.10.2023
With the exception of venous thromboembolism and pulmonary embolism events, the antiviral drug did not reduce the incidence of post-COVID-19 conditions in a study of nearly 10,000 US veterans. Medscape Medical News
Læs mereMedscape Infectious Diseases, 10.10.2023
Tilføjet 10.10.2023
The use of nirmatrelvir–ritonavir (Paxlovid) is associated with a lower risk for death or hospitalization in extremely vulnerable patients with COVID-19. Low-risk patients do not appear to benefit. Medscape Medical News
Læs mereMedscape Infectious Diseases, 23.09.2023
Tilføjet 23.09.2023
A real-world study found that Pfizer\'s COVID-19 antiviral Paxlovid is now less effective at preventing hospitalization or death in high-risk patients as compared with earlier studies. WebMD Health News
Læs mereMedscape Infectious Diseases, 20.09.2023
Tilføjet 20.09.2023
The American College of Physicians has issued an updated version of its living, rapid practice point guideline on the best treatment options for outpatients with confirmed COVID-19. MDedge News
Læs mereProMED, 30.05.2023
Tilføjet 30.05.2023
COVID-19 -- ChinaIn 2020, Catalonia saw 340 608 COVID-19 cases, among which there were 47 174 COVID-19-related hospitalizations (14%), 4,699 ICU admissions (1.4%), and 10 001 COVID-19-related deaths (3.0%). The median hospital stay was 7 days.Overall, higher annual average exposure to particle matter and nitrogen dioxide was associated with a greater risk (hazard) of COVID-19-related events. An increase in exposure to particle matter of 3.2 µg/m3 was associated with a 25% increase in hospital admissions
Læs mere